Engineering regulatory T cells against factor VIII inhibitors

Slides:

Advertisements

Similar presentations

Antigen Presentation K.J. Goodrum Department of Biomedical Sciences Ohio University 2005.

Advertisements

Dental Microbiology #211 IMMUNOLOGY 2006 Lecture 3.

T-cell & B cell receptors – role in immune response & Major Histocompatibility Complex (MHC) Lecture 6 4/10/2015.

Major Histocompatibility complex OR MHC MHC The principal function of T cells are : The principal function of T cells are : Defense against intracellular.

Cytokines are a diverse group of non- antibody proteins released by cells that act as intercellular mediators, especially in immune processes.

Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry by Po-Lin Chiu, George M. Bou-Assaf,

T-cell & B-cell receptors – Role in the Immune Response

Control of Th2-Mediated Inflammation by Regulatory T Cells

Socializing Individualized T-Cell Cancer Immunotherapy

Intracellular Pathogens Extracellular Pathogens

Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?

Major Histocompatibility complex OR

GVHD-associated immunodeficiency: soil or seed?

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

and CHAPTER 6 Major Histocompatibility Complex (MHC) Molecules

Do HSCs divide asymmetrically?

Major Histocompatibility complex OR

TCR-MHC-peptide(s): in vivo veritas

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Another Notch on the belt

Figure 1 Induction of immune tolerance

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

بنام خداي زيبائيها.

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

T regulatory cells turn on T regulatory cells

Gnawing at Metchnikoff’s paradigm

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Suppression, surprise: galectin-10 and Treg cells

Antigen-induced regulatory T cells

Taking a leaf from the book of oral tolerance

by Edward S. Morris, Kelli P. A. MacDonald, and Geoffrey R. Hill

T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.

by Sabah Sallah, and Jim Y. Wan

Rare cells predict GVHD

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

It Takes Two to Tango Immunity

Immune Tolerance to Self-Major Histocompatability Complex Class II Antigens after Bone Marrow Transplantation: Role of Regulatory T Cells Allan D. Hess,

Allan D. Hess Biology of Blood and Marrow Transplantation

Lymphoma spread? Target CD47-SIRPα!

Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients Bernard Lawrence Marini, Sung Won Choi, Craig Alan Byersdorfer, Simon.

Anergy: the CLL cell limbo

Nat. Rev. Rheumatol. doi: /nrrheum

Miki Ando, Hiromitsu Nakauchi Experimental Hematology

Kaitlin A. Read, Michael D. Powell, Paul W. McDonald, Kenneth J

Leonardo V. Riella, Mohamed H. Sayegh Kidney International Supplements

Figure 1 The role of CTLA4 and PD1 in T cell activation

Mechanism of CTLA-4-induced immunosuppression.

Current model of CD8+ T-cell central and effector memory generation for mouse and human T cells. Current model of CD8+ T-cell central and effector memory.

Dendritic cells: regulators of hepatic immunity or tolerance?

The Other Face of Chimeric Antigen Receptors

Schematic model of effector pathways that mediate tumor suppression by p53. Schematic model of effector pathways that mediate tumor suppression by p53.

Dietary Fat Inflames CD4+ T Cell Memory in Obesity

Immunology Dr. Refif S. Al-Shawk

Stefan H.E. Kaufmann, Shreemanta K. Parida Cell Host & Microbe

Are calcineurin inhibitors-free regimens ready for prime time?

Cell-mediated immunity Regulation of the immune response

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Gene targeting: Applications in transplantation research

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Alwi Shatry, Jackeline Chirinos, Michael A

Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers by Paul J Neeson, Alexander James Davenport, Joseph A Trapani, Michael.

A schematic presentation of secreted, endocytic, and signaling pattern-recognition receptors. A schematic presentation of secreted, endocytic, and signaling.

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Patient Tregs express normal levels of suppression.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor.

Presentation transcript:

Engineering regulatory T cells against factor VIII inhibitors by Paul C. Moorehead Blood Volume 125(7):1053-1054 February 12, 2015 ©2015 by American Society of Hematology

Interactions between engineered Tregs and effector T cells (Teffs). Interactions between engineered Tregs and effector T cells (Teffs). A gene construct encoding for a T-cell receptor (TCR) specific for FVIII peptide is transduced into polyclonal Tregs, producing Tregs expressing that TCR. Tregs interact with antigen-presenting cells (APCs) via human major histocompatibility complex II (MHCII), as do Teffs. Tregs exert suppressive effects on Teffs, preventing immune responses to antigen and promoting tolerance. Kim et al demonstrate in vitro that such engineered Tregs can suppress the typically polyclonal responses to whole FVIII, despite expressing TCRs specific for a single small FVIII peptide. Could this result in the off-target suppression of T-cell responses to non-FVIII antigens, such as antigens from pathogens or vaccines? Paul C. Moorehead Blood 2015;125:1053-1054 ©2015 by American Society of Hematology